-
Mashup Score: 0Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors - 2 year(s) ago
Purpose: 90Y-FF-21101 is an Yttrium-90–conjugated, chimeric mAb that is highly specific for binding to human placental (P)-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination in many cancer types. We report the clinical activity of 90Y-FF-21101 in a first-in-human phase I study in patients with advanced solid tumors. Patients…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors - 2 year(s) ago
Purpose: Entrectinib potently inhibits TRKA/B/C and ROS1, and previously induced deep (objective response rate [ORR] 57.4%) and durable (median duration of response [DoR] 10.4 months) responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This manuscript expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Updated analysis of entrectinib in #NTRK fusion+ cancers @CCR_AACR. In 121 adult pts with 14 tumor types, entrectinib RR 61%, mDOR 20m, intracranial RR 64%, intracranial mDOR 22m. Most toxicities grade 1-2 and reversible. FDA approved in 2019, EMA in 2020. https://t.co/mFVE3GHqyu
-
-
Mashup Score: 0
The coronavirus disease 2019 (COVID-19), now entering its third year, has led to major disruptions to economic stability, health care, and scientific research across the globe. To address the negative impact of COVID-19 on the cancer care continuum as well as the broader interruptions caused by the
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Just published! Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/cKM9FWLNzx https://t.co/6DcIyb29Xb
-
Just published! Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/Qvhdb0aNeT https://t.co/El7IDawZv3
-
Just published! Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/KteLsDokN8 https://t.co/ko3VPA0Doy
-
Just published! Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/IhJxKp9fdZ https://t.co/TdvrTmbb6p
-
-
Mashup Score: 0Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA) - 2 year(s) ago
Background: In patients with platinum-sensitive relapsed (PSR) ovarian cancer (OC), olaparib maintenance monotherapy significantly improves progression-free survival (PFS) versus placebo. However, evidence in the Asian population is lacking. This is the first study to evaluate olaparib efficacy and tolerability exclusively in Asian patients with PSR OC. Methods: Considering the limited placebo…
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical trial involving Chinese women with platinum-resistant ovarian cancer, olaparib maintenance was associated with a mPFS of 21.2 & 11.0 months in those with mutated or wild-type BRCA1/2, respectively; the incidence of grade ≥3 AEs was 48.7%: https://t.co/zGUL4MofWP #GynCSM
-
-
Mashup Score: 3
Purpose: We aimed to investigate genomic correlates underlying extremes of survivorship in metastatic colorectal cancer and their applicability in informing survival in distinct subsets of patients with metastatic colorectal cancer. Experimental Design: We examined differences in oncogenic somatic alterations between metastatic colorectal cancer cohorts demonstrating extremes of survivorship…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
@timnewhook19 @vreelant @CDTzeng @HopSTranCao @GregWilson152 @MDAndersonNews @TheAhpbaPodcast Mutation status absolutely matters!! In addition to 💪🏼body of work from @VautheyMD group @MDAndersonNews on RAS-TP53 cooperativity, we have reported on implications of RAS-TP53 co-alt in heterogeneous dz states in #metCRC & association w/ metastatic niche https://t.co/8OGlK8aVmB
-
-
Mashup Score: 2Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer - 2 year(s) ago
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) are effective in metastatic prostate cancer (PC), resistance occurs in most patients. This phase I/II trial assessed the safety, pharmacokinetic impact, and efficacy of the glucocorticoid receptor (GR) antagonist mifepristone (Mif) in combination with enzalutamide (Enz) for castration-resistant…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats Szmulewitz, @WalterStadler5 & team on 1st #prostatecancer GR antagon trial w/enz! No activity. But mifepristone actions are complex. Ahead are studies w/more specific #glucocorticoid blockers. @UCCancerCenter @PCF_Science https://t.co/uc4tvdB5kp
-
-
Mashup Score: 1Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells - 2 year(s) ago
Purpose: To characterize changes in the soft tissue sarcoma tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design. Experimental Design: Paired pre- and post-neoadjuvant therapy specimens were retrospectively identified for 32 patients with soft tissue sarcomas and analyzed by three modalities: multiplexed…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JTrentMDPhD: Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells https://t.co/iyVVeP3w6D
-
-
Mashup Score: 0Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer - 2 year(s) ago
Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are still lacking. Experimental design: We developed an isogenic cell-based platform to compare the oncogenic properties and specific therapeutic…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful paper from @DrMarkAwad, Pasi Janne, and Chiara Ambrogio analyzing functional and genomic differences in #NSCLC tumors harboring different #KRAS mutant isoforms. https://t.co/VmuqiM66Oj
-
-
Mashup Score: 2Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial - 2 year(s) ago
Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung cancers (NSCLC). Patients and Methods: In the global phase 1/2 LIBRETTO-001 trial ([NCT03157128][1]) in advanced RET -altered solid tumors, selpercatinib was dosed orally (160 mg twice every day) in 28-day cycles….
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial @CCR_AACR https://t.co/pTKhfJ58sf
-
-
Mashup Score: 1Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer - 2 year(s) ago
Background: Concurrent radiation therapy (RT) with cetuximab, an anti-EGFR monoclonal antibody (mAb), is a standard treatment for locally advanced head and neck squamous carcinoma (HNSCC). CTLA-4+ T regulatory cells (Treg) dampen cellular immunity and correlate negatively with clinical outcomes. This phase I study added anti-CTLA-4 mAb ipilimumab to cetuximab-RT. Methods: A [3 + 3] design…
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a phase I trial of ipilimumab plus cetuximab & RT in 18 pts with stage III‐IVb, high-risk (HPV-) or intermediate-risk (HPV+) HNSCC, 3-year DFS & OS were both 72%; High expression of PD1/LAG3/CD39 on tumour-infiltrating Tregs associated with worse DFS: https://t.co/6QuKViY5JM
-
Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors @CCR_AACR https://t.co/jF5tDHaki7